Hubbry Logo
AlloxanAlloxanMain
Open search
Alloxan
Community hub
Alloxan
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Alloxan
Alloxan
Alloxan
View on Wikipedia
from Wikipedia
Alloxan[1]
Alloxan
Alloxan monohydrate
Names
Preferred IUPAC name
5,5-Dihydroxypyrimidine-2,4,6(1H,3H,5H)-trione
Other names
5,5-Dihydroxybarbituric acid
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.000.057 Edit this at Wikidata
EC Number
  • 200-062-0
MeSH Alloxan
UNII
  • InChI=1S/C4H2N2O4/c7-1-2(8)5-4(10)6-3(1)9/h(H2,5,6,8,9,10) checkY
    Key: HIMXGTXNXJYFGB-UHFFFAOYSA-N checkY
  • InChI=1/C4H2N2O4/c7-1-2(8)5-4(10)6-3(1)9/h(H2,5,6,8,9,10)
    Key: HIMXGTXNXJYFGB-UHFFFAOYAQ
  • C1(=O)C(=O)NC(=O)NC1=O
Properties
C4H4N2O5 (monohydrate)
Molar mass 160.07 g/mol
Appearance pale yellow solid
Density 1.639 g/cm3 (anhydrous)
Melting point 254 °C (489 °F; 527 K) (decomposition)
0.29 g/100 mL[2]
Hazards
Safety data sheet (SDS) MSDS
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Alloxan, sometimes referred to as alloxan monohydrate, is an organic compound with the formula OC(NHCO)2C(OH)2. It is classified as a derivative of pyrimidine. The anhydrous derivative OC(NHCO)2CO is also known, as well as a dimeric derivative. These are some of the earliest known organic compounds. They exhibit a variety of biological activities.

History and literature

[edit]

The compound was discovered by Justus von Liebig and Friedrich Wöhler. It is one of the oldest named organic compounds. It was originally prepared in 1818 by Luigi Valentino Brugnatelli (1761-1818)[3][4] and was named in 1838 by Wöhler and Liebig.[5] The name "Alloxan" emerged from an amalgamation of the words "Allantoïn" and "Oxalsäure" (oxalic acid). The alloxan model of diabetes was first described in rabbits by Dunn, Sheehan and McLetchie in 1943.[6] The name is derived from allantoin, a product of uric acid excreted by the fetus into the allantois, and oxaluric acid derived from oxalic acid and urea, found in urine.

Alloxan was used in the production of the purple dye murexide, discovered by Carl Wilhelm Scheele in 1776. Murexide is the product of the complex in-situ multistep reaction of alloxantin and gaseous ammonia.[citation needed] Murexide results from the condensation of the unisolated intermediate uramil [de] with alloxan liberated during the course of the reaction.

Murexide dye (right) from reaction of alloxantin (left)

Scheele sourced uric acid from human calculi (such as kidney stones) and called the compound lithic acid. William Prout investigated the compound in 1818 and he used boa constrictor excrement with up to 90% ammonium acid urate.

In the chapter "Nitrogen" of his memoir The Periodic Table, Primo Levi tells of his futile attempt to make alloxan for a cosmetics manufacturer who has read that it can cause permanent reddening of the lips. Levi considers the droppings of pythons as a source for uric acid for making alloxan, but he is turned down by the director of the Turin zoo because the zoo already has lucrative contracts with pharmaceutical companies, so he is obliged to use chickens as his source of uric acid. The synthesis fails, however, "and the alloxan and its resonant name remained a resonant name."[7]

Synthesis

[edit]

It was originally obtained by oxidation of uric acid by nitric acid. It is prepared by oxidation of barbituric acid by chromium trioxide.[8]

Reactions

[edit]

Hydrolysis

[edit]

Alloxan is highly unstable in aqueous solution, undergoing hydrolysis to alloxanic acid. Under physiological conditions, alloxan has an estimated half-life of 1.5 minutes.[9]

Reduction

[edit]

Alloxan may be reduced to dialuric acid [de], which has a reductone structure, similar to ascorbic acid (Vitamin C).[10] However, unlike ascorbic acid, alloxan and dialuric acid have strong pro-oxidant physiological effects.

A dimeric derivative alloxantin can be prepared by partial reduction of alloxan with hydrogen sulfide.[2]

Alloxane (left) with dialuric acid (center) and alloxantin (right)

Alloxan monohydrate also undergoes one-electron reduction to form yellow salts containing a stable radical anion:[10]

2 C4H4N2O5 + 2 KCN → 2 [K+][C4H2N2O4•−] + (CN)2 + 2 H2O

Biological effects

[edit]

Alloxan is a toxic glucose analogue, which selectively destroys insulin-producing cells in the pancreas (that is, beta cells) when administered to rodents and many other animal species. This causes an insulin-dependent diabetes mellitus (called "alloxan diabetes") in these animals, with characteristics similar to type 1 diabetes in humans. Alloxan is selectively toxic to insulin-producing pancreatic beta cells because it preferentially accumulates in beta cells through uptake via the GLUT2 glucose transporter. Studies suggest alloxan does not cause diabetes in humans.[11] Others found a significant difference in alloxan plasma levels in children with and without type 1 diabetes.[12]

Reactive oxygen species generation

[edit]

Alloxan (C4H2N2O4) readily undergoes redox cycling with its one-electron (C4H3N2O4• semiquinone) and two-electron (dialuric acid, C4H4N2O4) reduction products.[13] In the presence of intracellular reductants such as glutathione (or other thiols), this generates reactive oxygen species (ROS) via interaction of alloxan reduction products with molecular oxygen and other redox-active species.[11] The beta cell toxic action of alloxan is initiated by free radicals formed in these redox reactions:[11]

C4H2N2O4 + GSH → C4H3N2O4• + GS•
C4H3N2O4• + GSH → C4H4N2O4 + GS•
C4H4N2O4 + O2 → C4H3N2O4• + O2•− + H+
C4H3N2O4• + O2 → C4H2N2O4 + O2•− + H+

Impact upon beta cells

[edit]

Because it selectively kills the insulin-producing beta-cells found in the pancreas, alloxan is used to induce diabetes in laboratory animals.[14][15] This occurs most likely because of selective uptake of the compound due to its structural similarity to glucose as well as the beta-cell's highly efficient uptake mechanism (GLUT2). In addition, alloxan has a high affinity to SH-containing cellular compounds and, as a result, reduces glutathione content. Furthermore, alloxan inhibits glucokinase, a SH-containing protein essential for insulin secretion induced by glucose.[16]

Most studies have shown that alloxan is not toxic to the human beta-cell, even in very high doses, probably because of differing glucose uptake mechanisms in humans and rodents.[17][18]

Alloxan is, however, toxic to the liver and the kidneys in high doses, as these are tissues where the GLUT2 transporter is expressed in humans.[11]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Alloxan

View on Grokipedia
from Grokipedia
Alloxan is an with the molecular formula C₄H₂N₂O₄ and the IUPAC name 1,3-diazinane-2,4,5,6-tetrone, commonly known as a derivative featuring four oxo groups. It appears as white to off-white orthorhombic crystals that sublime and decompose at 256 °C, with a molecular weight of 142.07 g/mol and in , acetone, alcohol, and . Primarily recognized in biomedical research for its selective toxicity to pancreatic β-cells, alloxan induces and experimental mellitus in animal models such as rats, mice, rabbits, and dogs by generating that damage insulin-producing cells. First synthesized in 1818 by Italian chemist Luigi Brugnatelli through the oxidation of uric acid, alloxan was one of the earliest pyrimidines produced artificially. Its name derives from allantoin (a product of uric acid metabolism) and oxalsäure (oxalic acid), reflecting its origins in early organic chemistry experiments by Friedrich Wöhler and Justus von Liebig, who advanced its synthesis from urea and uric acid derivatives starting in 1828. The compound's diabetogenic properties were discovered in 1942 by pathologist John Shaw Dunn and researcher Norman G. McLetchie at the University of Glasgow, who observed that a single intravenous injection in rabbits caused rapid onset of diabetes-like symptoms, including glycosuria and hyperglycemia, during wartime studies on renal pathology. Subsequent synthesis methods, such as the oxidation of barbituric acid with chromium trioxide, have optimized its production for laboratory use. In experimental settings, alloxan is administered typically at doses of 100–150 mg/kg to mimic , leading to symptoms like hyperlipemia, ketonemia, azoturia, and β-cell via mechanisms including from insulin granules and uptake through the GLUT2 . While human pancreatic β-cells show resistance due to lower GLUT2 expression, alloxan remains a cornerstone tool for studying pathophysiology, antidiabetic agents, and pancreatic regeneration, though has partially supplanted it for its stability and specificity. It also finds minor applications in and as a treatment for nesidioblastosis-induced by targeting hyperplastic β-cells. concerns include maternal and embryonic in at high doses and ocular in its tetrahydrate form, necessitating careful handling in research protocols.

Chemical Structure and Nomenclature

Molecular Formula and Structure

Alloxan has the molecular formula C₄H₂N₂O₄. A retained IUPAC name is 2,4,5,6(1H,3H)-pyrimidinetetrone. The molecule features a six-membered ring with oxo groups (=O) attached at carbon positions 2, 4, 5, and 6, resulting in a highly oxygenated heterocyclic structure. This arrangement positions the two nitrogen atoms at positions 1 and 3, with the ring exhibiting partial aromatic character due to conjugation between the carbonyl groups and the nitrogens. Alloxan can be viewed as a cyclic derivative, where the urea functionality is integrated into the framework, contributing to its reactivity and hydrogen-bonding capabilities. The compound undergoes enol-keto tautomerism, with the tetraketo form being the most stable in both gas and solution phases, although the form (such as 5,5-dihydroxypyrimidine-2,4,6(1H,3H)-trione) predominates under certain conditions. In aqueous solutions, alloxan readily forms a monohydrate, C₄H₂N₂O₄·H₂O, which is the common crystalline form and influences its structural depiction in hydrated environments. Crystallographic studies using and on the monohydrate reveal a planar ring conformation with precise bond lengths and angles; for example, data provide bond lengths corrected for thermal motion with e.s.d.s less than 0.002 and angles with e.s.d.s less than 0.1°, highlighting the effects of intramolecular hydrogen bonding and delocalization.

Naming Conventions

The name "Alloxan" was coined in 1838 by chemists and , derived from a combination of ""—a derivative excreted into the —and "oxalsäure," referring to or its derivative oxaluric acid. Common synonyms for alloxan include mesoxalylurea and 5,5-dihydroxybarbituric acid, the latter denoting its tautomeric enol form. The () Registry Number for the anhydrous form is 50-71-5, while the monohydrate form is assigned 2244-11-3. Alloxan is classified as a of , belonging to the broader class of pyrimidones and recognized as a substituted . In older chemical literature, alloxan was frequently referred to as the oxidation product of dialuric acid or , reflecting early synthetic routes via degradation. Modern International Union of Pure and Applied Chemistry (IUPAC) standardizes it as 2,4,5,6(1H,3H)-pyrimidinetetrone or, in systematic form, 1,3-diazinane-2,4,5,6-tetrone, emphasizing its fully oxygenated core.

Physical and Chemical Properties

Physical Characteristics

Alloxan is characteristically a white to off-white orthorhombic crystalline powder under standard conditions. The form possesses a molecular weight of 142.07 g/mol. It is odorless in its solid state. The compound decomposes at 256 °C. Its is 1.93 g/cm³. Alloxan demonstrates stability up to its decomposition temperature, sublimes in vacuo, and lacks a , as it decomposes before reaching such a . It may form a monohydrate upon hydration.

and Stability

Alloxan is highly soluble in , exceeding 50 g/L at 20°C, during which it readily forms a monohydrate. It is also soluble in polar organic solvents such as , , and acetone, while showing slight solubility in and ; however, it remains insoluble in non-polar solvents like . This solubility behavior stems from its multiple polar oxo groups, which facilitate interactions with protic and polar aprotic solvents. In aqueous media, alloxan produces acidic solutions and exhibits pH-dependent dissociation, with a reported pKa of 6.63 at 25°C. It demonstrates stability in acidic conditions, such as at 3, but undergoes rapid decomposition in alkaline environments. Solutions of alloxan are light-sensitive, necessitating storage away from light to prevent degradation, whereas the dry powder form remains shelf-stable under proper conditions. Alloxan engages in a rapid hydration equilibrium, forming its upon exposure to moist air or in aqueous solutions, which contributes to its efflorescent nature as a crystalline .

Synthesis

Historical Synthesis

Alloxan played an early role in the production of the dye , discovered through the oxidation of —a natural source rich in —by in 1776, where alloxan formed as a key intermediate in the multistep reaction leading to the final dye product. The compound was first isolated in pure form in by Italian chemist , who achieved this by oxidizing with , resulting in alloxan along with and various nitrogenous byproducts. This method marked alloxan as the earliest described derivative in chemical literature. Shortly after, in the late 1820s and 1830s, and further developed synthetic methods from and related compounds, naming the substance "alloxan" in 1838 after and oxalsäure (). Throughout the , synthetic approaches were refined, including the use of concentrated on or its derivatives like , as well as potassium oxidations, to improve accessibility for further study in . However, these early procedures generally suffered from variable yields and produced impure products contaminated by over-oxidation byproducts and incomplete reactions, necessitating laborious purification steps such as recrystallization.

Modern Preparation

The standard laboratory method for preparing alloxan involves the oxidation of using (CrO3) in a mixture of glacial acetic and . In this procedure, 128 g (1 mole) of is added portionwise over 25–30 minutes to a solution of 156 g (1.53 moles) CrO3 in 850 g glacial acetic and 100 ml , maintained at 50°C with stirring; the mixture is held at this temperature for an additional 25–30 minutes before cooling to 5–10°C to induce of alloxan monohydrate. This controlled temperature prevents decomposition of the product and contributes to yields of 75–78% (120–125 g). An alternative synthetic route entails the condensation of with mesoxalic acid to form the cyclic urea derivative, followed by oxidation to yield alloxan. Alloxan-type compounds, including alloxan itself, are recognized as cyclic condensates of and mesoxalic acid, providing a conceptual basis for this approach in settings. Dialuric acid, the reduced form related to this condensation pathway, can also be oxidized to alloxan using or other agents, though remains preferred for efficiency. Modern protocols emphasize yields up to 70–80% under optimized conditions, such as precise temperature control below 50°C to minimize side reactions and . Purification typically involves filtration of the crude product through a , followed by washing with cold glacial acetic acid until colorless and then with to remove impurities; the monohydrate form is obtained by recrystallization from hot water. Safety considerations are critical due to the use of strong oxidants like CrO3, which is toxic and requires proper ventilation and protective equipment to avoid exposure. Alloxan is not produced commercially at large scale, reflecting its niche role in biochemical research rather than industrial applications. These methods represent an evolution from historical oxidations, adapted for reliable laboratory-scale production.

Chemical Reactions

Hydrolysis

Alloxan undergoes in aqueous environments, primarily reacting with to form alloxanic acid as the initial product. This reaction is represented as alloxan + H₂O → alloxanic acid, where alloxanic acid is the ring-opened derivative of the structure, systematically named 4-hydroxy-2,5-dioxoimidazolidine-4-carboxylic acid. The process occurs rapidly under neutral or basic conditions, with the rate decreasing in acidic media due to of reactive sites that hinders nucleophilic approach. The mechanism involves nucleophilic attack by water (or hydroxide in basic media) on one of the carbonyl groups of the alloxan ring, leading to the formation of a tetrahedral intermediate followed by ring opening and tautomerization to yield alloxanic acid. This is irreversible and under physiological conditions. Alloxanic acid is further unstable and decomposes to and mesoxalic acid (oxomalonic acid), particularly upon heating or in alkaline conditions. At physiological (7.4) and 37°C, the of alloxan in phosphate buffer is approximately 1.5 minutes, reflecting its rapid decomposition and contributing to its short-lived presence in biological fluids. In contrast, solutions at 4 remain stable for several hours, allowing for longer storage under acidic conditions.

Reduction

Alloxan is reduced to dialuric acid, also known as 5-hydroxybarbituric acid, through the addition of two atoms across the 5-carbonyl group. This two-electron reduction is commonly achieved using mild reducing agents such as hydrogen gas in the presence of a catalyst, in aqueous media, or ascorbic acid in neutral conditions. The reaction proceeds under gentle conditions in aqueous or alcoholic solvents at ambient temperature and is reversible, with dialuric acid readily undergoing back to alloxan in the presence of oxygen. Dialuric acid, once formed, can further react by dimerization to alloxantin. These reduction-oxidation cycles between alloxan and dialuric acid serve as a key tool in for structural confirmation, particularly through polarographic waves and absorption spectroscopy that distinguish the states.

Biological Effects

Mechanism of Selective Toxicity

Alloxan exhibits selective toxicity toward pancreatic beta cells primarily due to its structural of glucose, allowing it to be recognized and transported by the , which is highly expressed on the surface of these cells. This glucose-like configuration enables alloxan to enter beta cells efficiently, as the molecule's hydrophilic nature and shape closely resemble glucose, facilitating uptake without inhibiting the transporter's function. In contrast, other cell types with lower GLUT2 expression, such as alpha cells or non-pancreatic tissues, experience minimal uptake, leading to preferential accumulation of alloxan in beta cells. Once inside the , alloxan is rapidly reduced by intracellular thiols, such as , to dialuric acid, a more polar and non-transportable derivative that cannot exit via the GLUT2 transporter. This intracellular trapping mechanism concentrates alloxan equivalents within s at levels significantly higher than in surrounding tissues—up to 10-fold greater uptake rates in high-GLUT2-expressing cells compared to those with lower expression—amplifying its toxic effects selectively in these glucose-sensing cells. The high GLUT2 density in s, which is essential for their role in glucose monitoring, thus becomes a vulnerability exploited by alloxan. As a thiol-reactive compound, alloxan binds to and inactivates , the key enzyme in beta cells responsible for glucose and sensing, with a half-maximal inhibitory concentration of 1–10 μmol/l. This inhibition disrupts glucose metabolism and ATP production without directly interfering with insulin pathways or responses to non-glucose secretagogues like . Consequently, the selective toxicity arises from alloxan's targeted entry, retention, and enzymatic disruption tailored to the unique physiology of beta cells.

Reactive Oxygen Species Generation

Alloxan induces primarily through auto-oxidation via a cycling mechanism involving its reduction product, dialuric acid. In this process, alloxan accepts an to form dialuric acid, which then rapidly reoxidizes in the presence of molecular oxygen, regenerating alloxan and producing anion radicals (O₂⁻). This cyclic reaction is depicted as: Alloxan+e−→Dialuric acid\text{Alloxan} + e^- \rightarrow \text{Dialuric acid} Dialuric acid+O2→Alloxan+O2⋅−\text{Dialuric acid} + \text{O}_2 \rightarrow \text{Alloxan} + \text{O}_2^{\cdot-} The redox cycling is facilitated by intracellular reducing agents, particularly thiols such as glutathione (GSH) and cysteine, which donate electrons to alloxan, leading to its reduction and the formation of oxidized glutathione (GSSG). This thiol-dependent process depletes cellular antioxidants like GSH, thereby amplifying reactive oxygen species (ROS) production and impairing the cell's defensive capacity against oxidative damage. The primary ROS generated is (O₂⁻), which undergoes enzymatic or spontaneous dismutation to (H₂O₂). In the presence of transition metals like iron, H₂O₂ participates in Fenton-like reactions to yield highly reactive hydroxyl radicals (•OH), exacerbating cellular . These ROS species—, , and hydroxyl radicals—collectively contribute to an oxidative burst that peaks within minutes of alloxan exposure, reflecting the rapid kinetics of the cycle. This swift generation of ROS is particularly pronounced due to alloxan's selective accumulation in susceptible cells via glucose transporters.

Impact on Pancreatic Beta Cells

Alloxan exerts its toxic effects on pancreatic beta cells primarily through the induction of and , mediated by (ROS) that cause DNA strand breaks, of cell membranes, and oxidation of critical proteins. These processes disrupt cellular integrity and function, leading to the selective destruction of insulin-producing beta cells while sparing other pancreatic cell types. ROS generation serves as the key mediator in this pathology, amplifying within the beta cells. The extent of beta cell destruction is highly dose-dependent, with intravenous or intraperitoneal administration of 100-200 mg/kg in typically resulting in 80-100% loss of s within 24-48 hours. Lower doses may cause partial damage, allowing for some functional recovery, whereas higher doses lead to near-total of the population. This rapid onset of correlates with the compound's accumulation in s via glucose transporters, exacerbating the oxidative burden. Following destruction, alloxan administration triggers a rapid onset of , with blood glucose levels elevating to 300-500 mg/dL within hours to days, mimicking the insulin deficiency of . At lower doses, this may be partially reversible if surviving s regenerate, but high doses result in irreversible damage due to permanent loss of insulin-secreting capacity. Sustained persists in affected models, reflecting the profound impairment in glucose . Histological examination of the in alloxan-treated reveals characteristic changes, including beta cell swelling, degranulation of insulin granules, and inflammatory infiltration in the islets of Langerhans. These alterations progress to complete loss of islet integrity within 12-48 hours at diabetogenic doses, with necrotic debris and evident in surviving cells. Such changes underscore the compound's utility in modeling beta cell-specific pathology.

Applications in Research

Induction of Experimental Diabetes

Alloxan is widely employed to induce experimental in , particularly rats and mice, through selective destruction of pancreatic s. The standard protocol involves administering alloxan monohydrate via intravenous or at doses ranging from 40 to 150 mg/kg body weight, with 120-150 mg/kg commonly used for high success rates in fasted animals to enhance uptake and minimize variability. Animals are typically fasted for 12-24 hours prior to injection to stabilize blood glucose and improve induction efficiency, followed by provision of 5-10% glucose solution orally or intraperitoneally 6-8 hours post-injection to counteract initial . This method results in rapid beta cell necrosis, leading to hypoinsulinemia and within 24-72 hours. The induced model exhibits characteristics mimicking , including sustained (blood glucose >250 mg/dL or 13.9 mmol/L), hypoinsulinemia with plasma insulin levels reduced to less than 50% of normal, , , and , persisting for 1-4 weeks before potential partial recovery or complications like . Confirmation of diabetes induction is achieved by measuring blood glucose levels exceeding 250 mg/dL on days 3-7 post-injection, often alongside reduced insulin concentrations via assays, ensuring at least 70-80% success rate in strains like Wistar rats or mice. The model's rapid onset allows for quick evaluation of antidiabetic interventions, though variability in response due to strain, age, and dose can affect reproducibility. Advantages of the alloxan model include its cost-effectiveness (approximately 1.5 USD per gram) and simplicity, enabling widespread use in pharmacological screening without specialized equipment. However, disadvantages encompass leading to 30-60% mortality from or renal failure, inconsistent duration due to alloxan's chemical instability , and non-reversibility in some cases. Ethical guidelines increasingly favor alternatives like for its greater stability and lower , particularly in protocols adhering to principles of the 3Rs (replacement, reduction, refinement) to minimize animal suffering.

Other Uses

Alloxan serves as a valuable model in studies for investigating (ROS)-mediated toxicity in diverse cell types, such as hepatocytes and neurons. In isolated rat hepatocytes, exposure to alloxan results in time- and concentration-dependent cellular damage, primarily through ROS generation, which can be mitigated by the presence of sugars like glucose, providing insights into protective mechanisms against oxidative injury in liver cells. Similarly, alloxan induces in neuronal cultures, mimicking ROS-related damage observed in neurodegenerative conditions and allowing researchers to assess neuroprotective agents. These applications leverage alloxan's ability to generate ROS via cycling with intracellular thiols, offering a controlled system to study cellular responses to oxidative insult without relying on diabetes models. In enzyme inhibition research, alloxan functions as a specific probe for studying the activity of and other -dependent enzymes due to its high reactivity with sulfhydryl groups. The compound's central 5-carbonyl group rapidly forms bonds with the thiol residues in glucokinase's , leading to irreversible inactivation with a half-maximal inhibitory concentration around 5 μM, which has been instrumental in elucidating the enzyme's role in glucose . This reactivity extends to broader investigations of -dependent enzymes, where alloxan helps probe structure-function relationships and potential therapeutic targets for modulating enzymatic activity in metabolic pathways. Alloxan plays a role in synthetic chemistry as a versatile intermediate for constructing and derivatives, particularly through reactions involving its core. For example, alloxan undergoes to yield murexide (ammonium purpurate), a key compound in purine-related syntheses and historical organic transformations. Its structural similarity to natural pyrimidines enables incorporation into more complex heterocycles, facilitating the development of analogs for biochemical and pharmaceutical applications. In , alloxan is integral to colorimetric assays for detection, where it forms as an intermediate during the oxidation of and subsequently reacts to produce murexide. Treatment of with generates alloxan, which, upon addition of , yields the characteristic purple murexide complex, enabling sensitive qualitative identification and quantitative measurement of metabolites in biological samples. This method, though qualitative in origin, has been adapted for spectrophotometric quantification, providing a simple tool for clinical and research analysis of . As a general cytotoxin, alloxan is employed in toxicity testing to screen compounds across various cell lines, exploiting its ROS-inducing properties to evaluate protective efficacy. In photometric assays, alloxan reduces cell viability in untreated cultures, an effect reversed by , thus serving as a benchmark for assessing compounds' ability to counteract oxidative damage in non-pancreatic models. This approach has been particularly useful in for novel targeting general cellular stress rather than specific metabolic disorders. As a glucose analogue, alloxan's selective uptake via glucose transporters enhances its utility in these targeted toxicity studies.

History

Discovery and Early Studies

In 1776, Swedish chemist oxidized derived from , a nitrogen-rich bird excrement, to produce murexide, a purple dye used as a synthetic analog of ancient pigments, though the involvement of alloxan as a key intermediate in this process was not recognized at the time. Scheele's work laid early groundwork for understanding transformations, focusing on its chemical reactivity rather than isolating specific products. The compound now known as alloxan was first isolated in 1818 by Italian chemist Luigi Brugnatelli through the oxidation of with , yielding a substance he named "ossieritrico" after its ability to produce red colors in reactions. Brugnatelli's isolation highlighted alloxan's role in uric acid degradation but did not fully characterize it, as analytical techniques of the era were limited. In 1838, German chemists and renamed the compound alloxan, deriving the name from "" (a purine degradation product found in fetal allantoic fluid) and "oxalsäure" (), while confirming its structure through synthesis from mesoxalic acid and , establishing it as a pyrimidine derivative related to . Their seminal paper detailed alloxan's formation during oxidation, linking it to and broader pathways. Throughout the , alloxan found primary application in dye chemistry, particularly for generating murexide to color and with purple hues, and featured in studies on purine degradation that connected it to and metabolism in biological contexts.

Development as a Diabetogenic Agent

In 1943, J. Shaw Dunn, Helen L. Sheehan, and N. G. B. McLetchie at the reported the selective induction of mellitus in rabbits following intravenous administration of alloxan, observing acute specifically in the of Langerhans. This finding, which built on prior observations of alloxan's chemical properties, established the compound as a tool for experimentally producing insulin-dependent through targeted destruction. Throughout the 1940s and 1950s, researchers including Arnold Lazarow conducted pivotal studies on alloxan's mechanisms, confirming its preferential toxicity to pancreatic s over other tissues. Lazarow's work demonstrated that sulfhydryl compounds like and cystine could protect against alloxan-induced in rats, indicating that alloxan's diabetogenic action involved interactions with groups essential for beta cell function. These investigations clarified the compound's specificity, distinguishing it from non-selective toxins and paving the way for its routine use in metabolic research. From the 1970s onward, mechanistic insights advanced significantly, revealing the roles of (ROS) and the GLUT2 in alloxan's selective toxicity. Alloxan, structurally analogous to glucose, is taken up by s via the low-affinity GLUT2 transporter, where it undergoes redox cycling with its reduction product dialuric acid to generate radicals and other ROS, overwhelming cellular defenses. Seminal reviews by Sigurd Lenzen on diabetogenic agents have synthesized this body of work, emphasizing how ROS-mediated damage, combined with GLUT2-mediated entry, underlies the compound's efficacy and tissue selectivity. Early enthusiasm for alloxan was tempered by controversies over its balance of specificity and , as some exhibited nephrotoxic effects and fatal renal failure, raising questions about off-target impacts beyond s. Protective effects of thiols further highlighted debates on whether alloxan's action was truly selective or partially attributable to general . These concerns contributed to a gradual shift toward , introduced in , which offered superior —avoiding alloxan's rapid in solution—and lower non-specific while achieving similar destruction via DNA . The development of alloxan as a diabetogenic agent has profoundly influenced research, with key literature such as Lenzen's 2008 Diabetologia review on its mechanisms garnering hundreds of citations and the overall model referenced in over 10,000 publications exploring glycemic control, insulin secretion, and therapeutic interventions.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Alloxan
  2. https://www.sciencedirect.com/topics/chemistry/alloxan
  3. https://pubmed.ncbi.nlm.nih.gov/12434795/
  4. https://pubmed.ncbi.nlm.nih.gov/6749588/
  5. https://cameochemicals.noaa.gov/chemical/19732
  6. https://www.chemspider.com/Chemical-Structure.5577.html
  7. https://www.acs.org/molecule-of-the-week/archive/a/alloxan.html
  8. https://webbook.nist.gov/cgi/cbook.cgi?ID=C50715&Units=SI
  9. https://www.sciencedirect.com/science/article/abs/pii/S2210271X12000631
  10. https://www.researchgate.net/publication/235991602_Tautomeric_transformations_and_reactivity_of_alloxan
  11. https://pubchem.ncbi.nlm.nih.gov/compound/Alloxan-monohydrate
  12. https://www.guidechem.com/dictionary_keys_alloxan.html
  13. https://doi.org/10.1107/S010827018500549X
  14. https://www.chemeurope.com/en/encyclopedia/Alloxan.html
  15. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4719885.htm
  16. https://datasheets.scbt.com/sds/aghs/en/sc-254940.pdf
  17. https://pubs.acs.org/doi/10.1021/ja00246a014
  18. https://www.sigmaaldrich.com/US/en/sds/aldrich/a7413
  19. https://www.gelatins.com.cn/product-889
  20. https://www.sciencedirect.com/topics/medicine-and-dentistry/alloxan
  21. https://www.researchgate.net/post/How_to_induce_diabetes_with_alloxan_in_mice
  22. http://www.orgsyn.org/demo.aspx?prep=CV4P0023
  23. https://www.mdpi.com/1420-3049/27/2/560
  24. https://doi.org/10.1016/S0021-9258(18)56013-0
  25. https://doi.org/10.1039/P29790001093
  26. https://doi.org/10.1016/S0021-9258(18)55669-6
  27. https://doi.org/10.1016/0006-2952(91)90449-F
  28. https://doi.org/10.1021/acsomega.1c06313
  29. https://pubs.acs.org/doi/10.1021/jo50001a011
  30. https://academic.oup.com/bcsj/article-pdf/52/11/3473/56097848/bcsj.52.3473.pdf
  31. https://ashpublications.org/blood/article/5/11/1062/7023/HEMOLYSIS-WITH-ALLOXAN-AND-ALLOXAN-LIKE-COMPOUNDS
  32. https://ir.library.oregonstate.edu/downloads/mc87pt181
  33. https://pubs.acs.org/doi/abs/10.1021/ja01060a055
  34. https://www.sciencedirect.com/science/article/abs/pii/S0022354915443898
  35. https://doi.org/10.1007/s00125-007-0886-7
  36. https://pubmed.ncbi.nlm.nih.gov/7593639/
  37. https://pubmed.ncbi.nlm.nih.gov/18087688/
  38. https://pubmed.ncbi.nlm.nih.gov/2536542/
  39. https://pubmed.ncbi.nlm.nih.gov/11829314/
  40. https://link.springer.com/article/10.1007/s00125-007-0886-7
  41. https://www.researchgate.net/publication/266461830_Alloxan_Induced_Diabetes_Mechanisms_and_Effects
  42. https://www.sciencedirect.com/science/article/pii/S1010660X18300107
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC11283676/
  44. https://pubmed.ncbi.nlm.nih.gov/34789130/
  45. https://www.sciencedirect.com/science/article/abs/pii/0006295282902854
  46. https://academic.oup.com/edrv/article/25/4/612/2355264
  47. https://pubmed.ncbi.nlm.nih.gov/8254288/
  48. https://pubs.rsc.org/en/content/articlehtml/1905/ct/ct9058701791
  49. https://www.researchgate.net/publication/282375622_Pharmacological_potentials_of_pyrimidine_derivative_A_review
  50. https://pubs.sciepub.com/wjoc/7/1/3/index.html
  51. https://www.researchgate.net/publication/334970119_On_the_Mechanism_of_the_Murexide_Reaction
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC1164564/
  53. https://books.rsc.org/books/monograph/2014/chapter/4615722/Out-of-the-Depths-Synthetic-Colors-From-the-Coal
  54. https://link.springer.com/article/10.1007/BF02341500
  55. https://pubmed.ncbi.nlm.nih.gov/3046975/
  56. https://doi.org/10.1007/BF02341500
  57. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)87397-3/fulltext
  58. https://pubmed.ncbi.nlm.nih.gov/20999696/
Add your contribution
Related Hubs
User Avatar
No comments yet.